News | Structural Heart | March 02, 2016

FDA Clears Sapien for Pulmonary Valve

The FDA approval expands use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve replacement procedures

Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve replacement procedures. The approval enables the treatment of adult and pediatric patients who suffer from either a narrowed pulmonary valve or moderate or greater pulmonary regurgitation caused by congenital heart disease.

"U.S. approval of the Sapien XT valve for pulmonic procedures provides an important, minimally invasive treatment option for a small group of patients who typically face the burden of multiple open-heart surgeries, oftentimes beginning at birth or during childhood. As risks increase with each open-heart surgery, a non-surgical option can help them receive treatment, recover and return to normal activities sooner," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.

FDA approval of the Edwards Sapien XT valve for pulmonic procedures was supported by data from the multicenter COMPASSION clinical trial and additional clinical data from Europe. As previously indicated, the commercial opportunity related to this approval is small and is factored into 2016 financial expectations.

For more information: www.edwards.com 

Related Content

William O'Neill, M.D., and Adam Greenbaum, M.D., perform a transcatheter aortic valve replacement (TAVR) procedure in the cath lab at Henry Ford Hospital in Detroit.

Podcast | Structural Heart | May 31, 2019
A discussion with William O...
Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning.  Interventional imagers created and interpret these images as part of the heart team.

Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning. The aortic valve is trileaflet with significant calcification (A). Annular measurements are performed to determine valve sizing (B). Coronary artery height is measured to predict the risk of coronary artery obstruction (C).  

Feature | Structural Heart | April 24, 2019 | Nadeen N. Faza, M.D., Dee Dee Wang, M.D., Joao Cavalcante, M.D., Andrew D. Choi, M.D., Jeffrey B. Geske, M.D., and Stephen H. Little, M.D.
Recent months have signaled a new and exciting era in the dynamic world of...
All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder.

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder. 

Feature | Structural Heart | March 28, 2019 | Jeff Zagoudis
Structural heart interventions represent one of the fastest growing segments of cardiology, as the number of devices
A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Overlay Init